86 related articles for article (PubMed ID: 21905534)
1. Refractory DKA as first presentation of acromegaly and a potential role for continuous venovenous hemofiltration in its successful management.
Mewawalla P; Jaiswal G; Moustakakis M; Sankaranarayanan N; Dasanu CA
Conn Med; 2011 Aug; 75(7):405-7. PubMed ID: 21905534
[TBL] [Abstract][Full Text] [Related]
2. Diabetic ketoacidosis in a patient with acromegaly.
Kopff B; Mucha S; Wolffenbuttel BH; Drzewoski J
Med Sci Monit; 2001; 7(1):142-7. PubMed ID: 11208511
[TBL] [Abstract][Full Text] [Related]
3. [Continuous blood purification therapy on 16 patients with diabetic ketoacidosis and acute kidney injury].
Yue RZ; Zhang L; Liu F; Fu P
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 May; 43(3):434-7. PubMed ID: 22812253
[TBL] [Abstract][Full Text] [Related]
4. Delivered dose of continuous venovenous hemofiltration predicts outcome in septic patients with acute kidney injury: a retrospective study.
Nurmohamed SA; Koning MV; Vervloet MG; Groeneveld AB
J Crit Care; 2011 Apr; 26(2):213-20. PubMed ID: 21036524
[TBL] [Abstract][Full Text] [Related]
5. Concurrent diagnosis of acromegaly and diabetic ketoacidosis.
Westphal SA
Endocr Pract; 2000; 6(6):450-2. PubMed ID: 11155217
[TBL] [Abstract][Full Text] [Related]
6. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
8. Biochemical markers of acromegaly: GH vs. IGF-I.
Barkan AL
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S97-100. PubMed ID: 15135787
[TBL] [Abstract][Full Text] [Related]
9. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
10. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
11. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
12. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
13. Biochemical evidence supporting the Cortina criteria.
von Werder K
J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
[TBL] [Abstract][Full Text] [Related]
14. A case of acromegaly complicated with diabetic ketoacidosis, pituitary apoplexy, and lymphoma.
Jiang HJ; Hung WW; Hsiao PJ
Kaohsiung J Med Sci; 2013 Dec; 29(12):687-90. PubMed ID: 24296058
[TBL] [Abstract][Full Text] [Related]
15. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
[TBL] [Abstract][Full Text] [Related]
16. Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature.
Erem C; Ersöz HO; Ukinç K; Avunduk AM; Hacihasanoglu A; Koçak M
Endocrine; 2006 Aug; 30(1):145-9. PubMed ID: 17185803
[TBL] [Abstract][Full Text] [Related]
17. IGF-I and mortality in patients with acromegaly.
Strasburger CJ
J Endocrinol Invest; 2005; 28(11 Suppl International):78-80. PubMed ID: 16625852
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[TBL] [Abstract][Full Text] [Related]
19. Pentobarbital Removal During Continuous Venovenous Hemofiltration: Case Report and Review of the Literature.
Hensler DM; McConnell DP; Levasseur-Franklin KE; Greathouse KM
J Pharm Pract; 2018 Dec; 31(6):682-686. PubMed ID: 29162023
[TBL] [Abstract][Full Text] [Related]
20. Quinine clearance in continuous venovenous hemofiltration.
Davies JG; Greenwood EF; Kingswood JC; Sharpstone P; Street MK
Ann Pharmacother; 1996 May; 30(5):487-90. PubMed ID: 8740330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
